SalubrisBio parent company Salubris Pharmaceuticals announces investment of $5M in GO Therapeutics (Cambridge, USA) to support development of their novel microinjection platform technology
By: jonadmin|Published on: Oct 27, 2020|Categories: |
Recent Posts
- Salubris Biotherapeutics Announces Positive Interim Data from the Phase 2 Trial of JK07 in Heart Failure
- Salubris Biotherapeutics Announces European Medicines Agency Approval to Initiate a Phase 1 Clinical Trial of JK06, a 5T4-Targeted ADC, in Solid Tumors
- Salubris Biotherapeutics Announces $35 Million in Financing and Provides Pipeline Progress Update
- Salubris Biotherapeutics Presents Positive Initial Data from Phase 1b/2 Clinical Trial of JK08 at the European Society for Medical Oncology Annual Congress 2023
- Salubris Biotherapeutics Presents Positive 6-Month Data from Phase 1b Clinical Trial of JK07 in Late-Breaking Session at The Heart Failure Society of America Annual Meeting 2023
Recent Comments